Literature DB >> 28631134

Budd-Chiari syndrome: outcomes of endovascular intervention-A single-center experience.

Nitin Jagtap1, Mithun Sharma2, Jagdeesh Singh2, Manu Tandan2, P N Rao2, Rajesh Gupta2, Sundeep Lakhtakia2, Mohan Ramchandani2, Harshal Shah2, T Mahesh Kumar2, Santosh Darishetty2, G V Rao2, D N Reddy2.   

Abstract

AIM: Outcomes of endovascular intervention in Budd-Chiari syndrome (BCS) have been reported with varied results. Clinical outcomes of endovascular interventions in BCS and role of various prognostic scores were critically evaluated in this study.
METHODS: This study retrospectively analyzed consecutive patients of BCS who underwent endovascular intervention between January 2007 and May 2016 at our center. Technical, clinical successes and complications were documented. The role of the prognostic scores such as Child-Turcotte-Pugh (CTP), model for end-stage liver disease (MELD), Rotterdam index, and original Clichy score in predicting mortality, clinical success, and need for re-interventions were also assessed.
RESULTS: A total of 88 patients were analyzed. The median follow up was 12 months (range 1-96 months). Thirteen (14.8%) patients had combined inferior vena cava (IVC) and hepatic vein (HV) obstruction; HV obstruction in 33 (37.5%) and inferior vena cava IVC obstruction in 42 (47.7%) patients. The following interventions were done: IVC angioplasty alone (n = 11), IVC angioplasty with stenting (n = 36), HV angioplasty with stenting (n = 26), combined HV and IVC stent (n = 2), and direct intrahepatic porto-systemic shunt (DIPS) (n = 13). Overall technical success was 87/88 (98.86%), and clinical success was 76/88 (86.36%). Immediate complications were noted in 8 patients (10%). The 1-, 2-, 3-, and 4-year stent patency rates were 90.91%, 81.08%, 74.59%, and 70.45%, respectively. Re-interventions were required in 15 (17%). Overall mortality was 6 (6.8%). Apart from MELD >14, none of the other prognostic score could predict mortality, clinical success, and need for re-interventions.
CONCLUSION: Endovascular interventions play an important role in the management of BCS, in properly selected patients, even if prognostic score is unfavorable.

Entities:  

Keywords:  Budd-Chiari syndrome; DIPS; Endovascular interventions; Prognostic scores

Mesh:

Year:  2017        PMID: 28631134     DOI: 10.1007/s12664-017-0760-6

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  40 in total

1.  Vascular disorders of the liver.

Authors:  Laurie D DeLeve; Dominique-Charles Valla; Guadalupe Garcia-Tsao
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

2.  Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis.

Authors:  A E Mahmoud; A S Helmy; L Billingham; E Elias
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-05       Impact factor: 2.566

3.  Budd-Chiari syndrome in childhood secondary to inferior vena caval obstruction.

Authors:  A Taneja; S K Mitra; P D Moghe; P N Rao; N Samanta; L Kumar
Journal:  Pediatrics       Date:  1979-05       Impact factor: 7.124

4.  Comparison of ultrasonography, computed tomography and 99mTc liver scan in diagnosis of Budd-Chiari syndrome.

Authors:  S Gupta; S Barter; G W Phillips; R N Gibson; H J Hodgson
Journal:  Gut       Date:  1987-03       Impact factor: 23.059

5.  TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy.

Authors:  Antonia Perelló; Juan Carlos García-Pagán; Rosa Gilabert; Yanette Suárez; Eduardo Moitinho; Francisco Cervantes; Juan Carlos Reverter; Angels Escorsell; Jaume Bosch; Juan Rodés
Journal:  Hepatology       Date:  2002-01       Impact factor: 17.425

6.  Managing Budd-Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting.

Authors:  N C Fisher; I McCafferty; M Dolapci; M Wali; J A Buckels; S P Olliff; E Elias
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

7.  Management of hepatic venous outflow obstruction.

Authors:  V Kohli; G K Pande; V Dev; K S Reddy; U Kaul; S Nundy
Journal:  Lancet       Date:  1993-09-18       Impact factor: 79.321

Review 8.  Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature.

Authors:  J B Dilawari; P Bambery; Y Chawla; U Kaur; S R Bhusnurmath; H S Malhotra; G K Sood; S K Mitra; S K Khanna; B S Walia
Journal:  Medicine (Baltimore)       Date:  1994-01       Impact factor: 1.889

9.  TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience.

Authors:  Andrea Mancuso; Konrad Fung; Maria Mela; John Tibballs; Anthony Watkinson; Andrew K Burroughs; David Patch
Journal:  J Hepatol       Date:  2003-06       Impact factor: 25.083

10.  Diagnostic value of combined transhepatic venography and inferior vena cavography in chronic Budd-Chiari syndrome.

Authors:  D V Datta; S Vashishta; A K Samanta; P N Chhuttani
Journal:  Am J Dig Dis       Date:  1978-11
View more
  3 in total

1.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

2.  Evaluation of outcome from endovascular therapy for Budd-Chiari syndrome: a systematic review and meta-analysis.

Authors:  Gauri Mukhiya; Xueliang Zhou; Xinwei Han; Dechao Jiao; Gaurab Pokhrel; Yahua Li; Sita Pokhrel
Journal:  Sci Rep       Date:  2022-09-28       Impact factor: 4.996

Review 3.  An Update on the Management of Budd-Chiari Syndrome.

Authors:  A Sharma; S N Keshava; A Eapen; E Elias; C E Eapen
Journal:  Dig Dis Sci       Date:  2020-07-20       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.